News - ExCellThera

November 3, 2023

ExCellThera announces new UM171 data to be presented at ASH 2023

ExCellThera Inc. (ExCellThera), a world leader in blood stem cell expansion and fitness, announced today several UM171 presentations, including an oral session on new data from Phase 2 studies of investigational UM171 cell therapy in high-risk blood cancer patients...

ExCellThera to present at the 2023 Cell & Gene Meeting on the Mesa Conference

ExCellThera Inc. (ExCellThera), a world leader in blood stem cell expansion and rejuvenation, announced today that David Millette, CEO, will present in person at the annual Cell & Gene Meeting on the Mesa conference to be held on October 10-12, 2023, at the Park Hyatt Aviara Resort in Carlsbad, California.

UM171 cell therapy demonstrates improved outcomes compared to cord and matched unrelated donor peripheral blood transplants in real-world setting

ExCellThera Inc. (ExCellThera), a world leader in blood stem cell expansion and rejuvenation, announced today findings from a safety and efficacy retrospective analysis comparing outcomes of patients treated with ECT-001 (UM171-expanded) Cell Therapy in a Phase 1/2 trial to those treated with cord blood and matched unrelated donor peripheral blood stem cell transplants.